The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Vaccin Antirabic Market Research Report 2024
Synopsis
Rabies vaccine is a vaccine to prevent the occurrence of rabies.The vaccine is very good at preventing wound infection.It can be divided into two types: one is post-exposure (bite, scratch) prevention, and the other is pre-exposure (no bite, scratch) prevention.
The global Vaccin Antirabic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Vaccin Antirabic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaccin Antirabic.
Report Scope
The Vaccin Antirabic market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Vaccin Antirabic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vaccin Antirabic manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Sanofi
Chengda
Yisheng
Merck
VACN
Changsheng
BCHT
Hissen
Zhongke Biological
Ningbo Rongan Biological Pharmaceutical
Guangzhou Nuocheng Biological
Segment by Type
Gopher Kidney Cell Vaccine
Freeze-Dried Vero Cell Vaccine
Common Vero Cell Vaccines
Human Diploid Vaccine
Segment by Application
Pre-exposure Prophylaxis
After Exposure Prophylaxis
Additional Doses
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vaccin Antirabic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vaccin Antirabic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Rabies vaccine is a vaccine to prevent the occurrence of rabies.The vaccine is very good at preventing wound infection.It can be divided into two types: one is post-exposure (bite, scratch) prevention, and the other is pre-exposure (no bite, scratch) prevention.
The global Vaccin Antirabic market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Vaccin Antirabic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vaccin Antirabic.
Report Scope
The Vaccin Antirabic market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Vaccin Antirabic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Vaccin Antirabic manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Sanofi
Chengda
Yisheng
Merck
VACN
Changsheng
BCHT
Hissen
Zhongke Biological
Ningbo Rongan Biological Pharmaceutical
Guangzhou Nuocheng Biological
Segment by Type
Gopher Kidney Cell Vaccine
Freeze-Dried Vero Cell Vaccine
Common Vero Cell Vaccines
Human Diploid Vaccine
Segment by Application
Pre-exposure Prophylaxis
After Exposure Prophylaxis
Additional Doses
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Vaccin Antirabic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Vaccin Antirabic in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Vaccin Antirabic Market Overview
1.1 Product Overview and Scope of Vaccin Antirabic
1.2 Vaccin Antirabic Segment by Type
1.2.1 Global Vaccin Antirabic Market Value Comparison by Type (2024-2030)
1.2.2 Gopher Kidney Cell Vaccine
1.2.3 Freeze-Dried Vero Cell Vaccine
1.2.4 Common Vero Cell Vaccines
1.2.5 Human Diploid Vaccine
1.3 Vaccin Antirabic Segment by Application
1.3.1 Global Vaccin Antirabic Market Value by Application: (2024-2030)
1.3.2 Pre-exposure Prophylaxis
1.3.3 After Exposure Prophylaxis
1.3.4 Additional Doses
1.4 Global Vaccin Antirabic Market Size Estimates and Forecasts
1.4.1 Global Vaccin Antirabic Revenue 2019-2030
1.4.2 Global Vaccin Antirabic Sales 2019-2030
1.4.3 Global Vaccin Antirabic Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Vaccin Antirabic Market Competition by Manufacturers
2.1 Global Vaccin Antirabic Sales Market Share by Manufacturers (2019-2024)
2.2 Global Vaccin Antirabic Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Vaccin Antirabic Average Price by Manufacturers (2019-2024)
2.4 Global Vaccin Antirabic Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Vaccin Antirabic, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Vaccin Antirabic, Product Type & Application
2.7 Vaccin Antirabic Market Competitive Situation and Trends
2.7.1 Vaccin Antirabic Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Vaccin Antirabic Players Market Share by Revenue
2.7.3 Global Vaccin Antirabic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Vaccin Antirabic Retrospective Market Scenario by Region
3.1 Global Vaccin Antirabic Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Vaccin Antirabic Global Vaccin Antirabic Sales by Region: 2019-2030
3.2.1 Global Vaccin Antirabic Sales by Region: 2019-2024
3.2.2 Global Vaccin Antirabic Sales by Region: 2025-2030
3.3 Global Vaccin Antirabic Global Vaccin Antirabic Revenue by Region: 2019-2030
3.3.1 Global Vaccin Antirabic Revenue by Region: 2019-2024
3.3.2 Global Vaccin Antirabic Revenue by Region: 2025-2030
3.4 North America Vaccin Antirabic Market Facts & Figures by Country
3.4.1 North America Vaccin Antirabic Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Vaccin Antirabic Sales by Country (2019-2030)
3.4.3 North America Vaccin Antirabic Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Vaccin Antirabic Market Facts & Figures by Country
3.5.1 Europe Vaccin Antirabic Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Vaccin Antirabic Sales by Country (2019-2030)
3.5.3 Europe Vaccin Antirabic Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Vaccin Antirabic Market Facts & Figures by Country
3.6.1 Asia Pacific Vaccin Antirabic Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Vaccin Antirabic Sales by Country (2019-2030)
3.6.3 Asia Pacific Vaccin Antirabic Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Vaccin Antirabic Market Facts & Figures by Country
3.7.1 Latin America Vaccin Antirabic Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Vaccin Antirabic Sales by Country (2019-2030)
3.7.3 Latin America Vaccin Antirabic Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Vaccin Antirabic Market Facts & Figures by Country
3.8.1 Middle East and Africa Vaccin Antirabic Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Vaccin Antirabic Sales by Country (2019-2030)
3.8.3 Middle East and Africa Vaccin Antirabic Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Vaccin Antirabic Sales by Type (2019-2030)
4.1.1 Global Vaccin Antirabic Sales by Type (2019-2024)
4.1.2 Global Vaccin Antirabic Sales by Type (2025-2030)
4.1.3 Global Vaccin Antirabic Sales Market Share by Type (2019-2030)
4.2 Global Vaccin Antirabic Revenue by Type (2019-2030)
4.2.1 Global Vaccin Antirabic Revenue by Type (2019-2024)
4.2.2 Global Vaccin Antirabic Revenue by Type (2025-2030)
4.2.3 Global Vaccin Antirabic Revenue Market Share by Type (2019-2030)
4.3 Global Vaccin Antirabic Price by Type (2019-2030)
5 Segment by Application
5.1 Global Vaccin Antirabic Sales by Application (2019-2030)
5.1.1 Global Vaccin Antirabic Sales by Application (2019-2024)
5.1.2 Global Vaccin Antirabic Sales by Application (2025-2030)
5.1.3 Global Vaccin Antirabic Sales Market Share by Application (2019-2030)
5.2 Global Vaccin Antirabic Revenue by Application (2019-2030)
5.2.1 Global Vaccin Antirabic Revenue by Application (2019-2024)
5.2.2 Global Vaccin Antirabic Revenue by Application (2025-2030)
5.2.3 Global Vaccin Antirabic Revenue Market Share by Application (2019-2030)
5.3 Global Vaccin Antirabic Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Corporation Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GSK Vaccin Antirabic Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Vaccin Antirabic Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Chengda
6.3.1 Chengda Corporation Information
6.3.2 Chengda Description and Business Overview
6.3.3 Chengda Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Chengda Vaccin Antirabic Product Portfolio
6.3.5 Chengda Recent Developments/Updates
6.4 Yisheng
6.4.1 Yisheng Corporation Information
6.4.2 Yisheng Description and Business Overview
6.4.3 Yisheng Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Yisheng Vaccin Antirabic Product Portfolio
6.4.5 Yisheng Recent Developments/Updates
6.5 Merck
6.5.1 Merck Corporation Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck Vaccin Antirabic Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 VACN
6.6.1 VACN Corporation Information
6.6.2 VACN Description and Business Overview
6.6.3 VACN Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.6.4 VACN Vaccin Antirabic Product Portfolio
6.6.5 VACN Recent Developments/Updates
6.7 Changsheng
6.6.1 Changsheng Corporation Information
6.6.2 Changsheng Description and Business Overview
6.6.3 Changsheng Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Changsheng Vaccin Antirabic Product Portfolio
6.7.5 Changsheng Recent Developments/Updates
6.8 BCHT
6.8.1 BCHT Corporation Information
6.8.2 BCHT Description and Business Overview
6.8.3 BCHT Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.8.4 BCHT Vaccin Antirabic Product Portfolio
6.8.5 BCHT Recent Developments/Updates
6.9 Hissen
6.9.1 Hissen Corporation Information
6.9.2 Hissen Description and Business Overview
6.9.3 Hissen Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Hissen Vaccin Antirabic Product Portfolio
6.9.5 Hissen Recent Developments/Updates
6.10 Zhongke Biological
6.10.1 Zhongke Biological Corporation Information
6.10.2 Zhongke Biological Description and Business Overview
6.10.3 Zhongke Biological Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Zhongke Biological Vaccin Antirabic Product Portfolio
6.10.5 Zhongke Biological Recent Developments/Updates
6.11 Ningbo Rongan Biological Pharmaceutical
6.11.1 Ningbo Rongan Biological Pharmaceutical Corporation Information
6.11.2 Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Description and Business Overview
6.11.3 Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Product Portfolio
6.11.5 Ningbo Rongan Biological Pharmaceutical Recent Developments/Updates
6.12 Guangzhou Nuocheng Biological
6.12.1 Guangzhou Nuocheng Biological Corporation Information
6.12.2 Guangzhou Nuocheng Biological Vaccin Antirabic Description and Business Overview
6.12.3 Guangzhou Nuocheng Biological Vaccin Antirabic Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Guangzhou Nuocheng Biological Vaccin Antirabic Product Portfolio
6.12.5 Guangzhou Nuocheng Biological Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Vaccin Antirabic Industry Chain Analysis
7.2 Vaccin Antirabic Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Vaccin Antirabic Production Mode & Process
7.4 Vaccin Antirabic Sales and Marketing
7.4.1 Vaccin Antirabic Sales Channels
7.4.2 Vaccin Antirabic Distributors
7.5 Vaccin Antirabic Customers
8 Vaccin Antirabic Market Dynamics
8.1 Vaccin Antirabic Industry Trends
8.2 Vaccin Antirabic Market Drivers
8.3 Vaccin Antirabic Market Challenges
8.4 Vaccin Antirabic Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Vaccin Antirabic Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Vaccin Antirabic Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Vaccin Antirabic Market Competitive Situation by Manufacturers in 2023
Table 4. Global Vaccin Antirabic Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Vaccin Antirabic Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Vaccin Antirabic Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Vaccin Antirabic Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Vaccin Antirabic Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Vaccin Antirabic, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Vaccin Antirabic, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Vaccin Antirabic, Product Type & Application
Table 12. Global Key Manufacturers of Vaccin Antirabic, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Vaccin Antirabic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vaccin Antirabic as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Vaccin Antirabic Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Vaccin Antirabic Sales by Region (2019-2024) & (K Units)
Table 18. Global Vaccin Antirabic Sales Market Share by Region (2019-2024)
Table 19. Global Vaccin Antirabic Sales by Region (2025-2030) & (K Units)
Table 20. Global Vaccin Antirabic Sales Market Share by Region (2025-2030)
Table 21. Global Vaccin Antirabic Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Vaccin Antirabic Revenue Market Share by Region (2019-2024)
Table 23. Global Vaccin Antirabic Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Vaccin Antirabic Revenue Market Share by Region (2025-2030)
Table 25. North America Vaccin Antirabic Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Vaccin Antirabic Sales by Country (2019-2024) & (K Units)
Table 27. North America Vaccin Antirabic Sales by Country (2025-2030) & (K Units)
Table 28. North America Vaccin Antirabic Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Vaccin Antirabic Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Vaccin Antirabic Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Vaccin Antirabic Sales by Country (2019-2024) & (K Units)
Table 32. Europe Vaccin Antirabic Sales by Country (2025-2030) & (K Units)
Table 33. Europe Vaccin Antirabic Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Vaccin Antirabic Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Vaccin Antirabic Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Vaccin Antirabic Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Vaccin Antirabic Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Vaccin Antirabic Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Vaccin Antirabic Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Vaccin Antirabic Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Vaccin Antirabic Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Vaccin Antirabic Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Vaccin Antirabic Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Vaccin Antirabic Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Vaccin Antirabic Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Vaccin Antirabic Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Vaccin Antirabic Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Vaccin Antirabic Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Vaccin Antirabic Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Vaccin Antirabic Sales (K Units) by Type (2019-2024)
Table 51. Global Vaccin Antirabic Sales (K Units) by Type (2025-2030)
Table 52. Global Vaccin Antirabic Sales Market Share by Type (2019-2024)
Table 53. Global Vaccin Antirabic Sales Market Share by Type (2025-2030)
Table 54. Global Vaccin Antirabic Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Vaccin Antirabic Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Vaccin Antirabic Revenue Market Share by Type (2019-2024)
Table 57. Global Vaccin Antirabic Revenue Market Share by Type (2025-2030)
Table 58. Global Vaccin Antirabic Price (US$/Unit) by Type (2019-2024)
Table 59. Global Vaccin Antirabic Price (US$/Unit) by Type (2025-2030)
Table 60. Global Vaccin Antirabic Sales (K Units) by Application (2019-2024)
Table 61. Global Vaccin Antirabic Sales (K Units) by Application (2025-2030)
Table 62. Global Vaccin Antirabic Sales Market Share by Application (2019-2024)
Table 63. Global Vaccin Antirabic Sales Market Share by Application (2025-2030)
Table 64. Global Vaccin Antirabic Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Vaccin Antirabic Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Vaccin Antirabic Revenue Market Share by Application (2019-2024)
Table 67. Global Vaccin Antirabic Revenue Market Share by Application (2025-2030)
Table 68. Global Vaccin Antirabic Price (US$/Unit) by Application (2019-2024)
Table 69. Global Vaccin Antirabic Price (US$/Unit) by Application (2025-2030)
Table 70. GSK Corporation Information
Table 71. GSK Description and Business Overview
Table 72. GSK Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. GSK Vaccin Antirabic Product
Table 74. GSK Recent Developments/Updates
Table 75. Sanofi Corporation Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Sanofi Vaccin Antirabic Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Chengda Corporation Information
Table 81. Chengda Description and Business Overview
Table 82. Chengda Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Chengda Vaccin Antirabic Product
Table 84. Chengda Recent Developments/Updates
Table 85. Yisheng Corporation Information
Table 86. Yisheng Description and Business Overview
Table 87. Yisheng Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Yisheng Vaccin Antirabic Product
Table 89. Yisheng Recent Developments/Updates
Table 90. Merck Corporation Information
Table 91. Merck Description and Business Overview
Table 92. Merck Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Merck Vaccin Antirabic Product
Table 94. Merck Recent Developments/Updates
Table 95. VACN Corporation Information
Table 96. VACN Description and Business Overview
Table 97. VACN Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. VACN Vaccin Antirabic Product
Table 99. VACN Recent Developments/Updates
Table 100. Changsheng Corporation Information
Table 101. Changsheng Description and Business Overview
Table 102. Changsheng Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Changsheng Vaccin Antirabic Product
Table 104. Changsheng Recent Developments/Updates
Table 105. BCHT Corporation Information
Table 106. BCHT Description and Business Overview
Table 107. BCHT Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. BCHT Vaccin Antirabic Product
Table 109. BCHT Recent Developments/Updates
Table 110. Hissen Corporation Information
Table 111. Hissen Description and Business Overview
Table 112. Hissen Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Hissen Vaccin Antirabic Product
Table 114. Hissen Recent Developments/Updates
Table 115. Zhongke Biological Corporation Information
Table 116. Zhongke Biological Description and Business Overview
Table 117. Zhongke Biological Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Zhongke Biological Vaccin Antirabic Product
Table 119. Zhongke Biological Recent Developments/Updates
Table 120. Ningbo Rongan Biological Pharmaceutical Corporation Information
Table 121. Ningbo Rongan Biological Pharmaceutical Description and Business Overview
Table 122. Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Ningbo Rongan Biological Pharmaceutical Vaccin Antirabic Product
Table 124. Ningbo Rongan Biological Pharmaceutical Recent Developments/Updates
Table 125. Guangzhou Nuocheng Biological Corporation Information
Table 126. Guangzhou Nuocheng Biological Description and Business Overview
Table 127. Guangzhou Nuocheng Biological Vaccin Antirabic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Guangzhou Nuocheng Biological Vaccin Antirabic Product
Table 129. Guangzhou Nuocheng Biological Recent Developments/Updates
Table 130. Key Raw Materials Lists
Table 131. Raw Materials Key Suppliers Lists
Table 132. Vaccin Antirabic Distributors List
Table 133. Vaccin Antirabic Customers List
Table 134. Vaccin Antirabic Market Trends
Table 135. Vaccin Antirabic Market Drivers
Table 136. Vaccin Antirabic Market Challenges
Table 137. Vaccin Antirabic Market Restraints
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Vaccin Antirabic
Figure 2. Global Vaccin Antirabic Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Vaccin Antirabic Market Share by Type in 2023 & 2030
Figure 4. Gopher Kidney Cell Vaccine Product Picture
Figure 5. Freeze-Dried Vero Cell Vaccine Product Picture
Figure 6. Common Vero Cell Vaccines Product Picture
Figure 7. Human Diploid Vaccine Product Picture
Figure 8. Global Vaccin Antirabic Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Vaccin Antirabic Market Share by Application in 2023 & 2030
Figure 10. Pre-exposure Prophylaxis
Figure 11. After Exposure Prophylaxis
Figure 12. Additional Doses
Figure 13. Global Vaccin Antirabic Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Vaccin Antirabic Market Size (2019-2030) & (US$ Million)
Figure 15. Global Vaccin Antirabic Sales (2019-2030) & (K Units)
Figure 16. Global Vaccin Antirabic Average Price (US$/Unit) & (2019-2030)
Figure 17. Vaccin Antirabic Report Years Considered
Figure 18. Vaccin Antirabic Sales Share by Manufacturers in 2023
Figure 19. Global Vaccin Antirabic Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Vaccin Antirabic Players: Market Share by Revenue in 2023
Figure 21. Vaccin Antirabic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Vaccin Antirabic Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Vaccin Antirabic Sales Market Share by Country (2019-2030)
Figure 24. North America Vaccin Antirabic Revenue Market Share by Country (2019-2030)
Figure 25. U.S. Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Vaccin Antirabic Sales Market Share by Country (2019-2030)
Figure 28. Europe Vaccin Antirabic Revenue Market Share by Country (2019-2030)
Figure 29. Germany Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Vaccin Antirabic Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Vaccin Antirabic Revenue Market Share by Region (2019-2030)
Figure 36. China Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Taiwan Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Philippines Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Vaccin Antirabic Sales Market Share by Country (2019-2030)
Figure 47. Latin America Vaccin Antirabic Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Vaccin Antirabic Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Vaccin Antirabic Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. UAE Vaccin Antirabic Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Vaccin Antirabic by Type (2019-2030)
Figure 57. Global Revenue Market Share of Vaccin Antirabic by Type (2019-2030)
Figure 58. Global Vaccin Antirabic Price (US$/Unit) by Type (2019-2030)
Figure 59. Global Sales Market Share of Vaccin Antirabic by Application (2019-2030)
Figure 60. Global Revenue Market Share of Vaccin Antirabic by Application (2019-2030)
Figure 61. Global Vaccin Antirabic Price (US$/Unit) by Application (2019-2030)
Figure 62. Vaccin Antirabic Value Chain
Figure 63. Vaccin Antirabic Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
